Early investigational drugs targeting PPAR-α for the treatment of metabolic disease
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The fibrates have been used for many years to treat dyslipidemias and have also recently been shown to have anti-inflammatory effects. They are relatively weak PPAR-α agonists and do have some adverse effects. Novel compounds are in development, which are selective PPAR modulators (SPPARMs) and have more potent PPAR-α agonist activity. These may prove to have advantages in the treatment of dyslipidemia, insulin resistance and non-alcoholic fatty liver disease (NAFLD). AREAS COVERED: This review focuses on PPAR-α agonists or SPPARMs in development describing the preclinical and early clinical studies. The information was obtained by searching the published literature and abstracts from recent meetings. Ongoing clinical trials were identified using the Clinicaltrial.gov database. EXPERT OPINION: There is still a need for new drugs to treat atherogenic dyslipidemia. The highly potent and selective PPAR-α agonist K-877 has shown beneficial effects on atherogenic dyslipidemia and absence of some adverse effects seen with fibrates. The dual PPAR-α/PPAR-δ agonist GFT-505 has shown favorable results in improving atherogenic dyslipidemia and insulin resistance and appears to be a potential candidate for the treatment of NAFLD. Long-term trials are needed to assess the safety and efficacy of these new agents for cardiovascular and liver outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439 · cited 1×
“Before the use of statins, clinical trials with gemfibrozil showed beneficial effects on cardiovascular events in the Helsinki Heart Study [26] and the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial study [27].”
MethodEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · cited 1×
“The cholesterol ester transport protein inhibitors provide an attractive new mechanism for increasing HDL-C and reducing LDL-C but the failure in Phase III trials of torcetrapib with off-target effects including increase in blood pressure [78], and of dalcetrapib in the dal-OUTCOMES study for futility are disappointin…”
BackgroundNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 1×
“The more recent Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid study tested whether the addition of fenofibrate to treatment with simvastatin in patients with T2DM at high risk of CVD could improve the combined cardiovascular event outcome [34].”
BackgroundMajor lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 2×
“Similar findings were noted in the secondary prevention Bezafibrate Infarction Prevention study where bezafibrate did not significantly reduce the primary end point in the overall study but did reduce it in a sub group of patients with high baseline triglycerides (‡ 200 mg/dl or 2.3 mmol/l) and in a later analysis ide…”
InfluentialEffects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668 · cited 1×
“The two large studies that examined the addition of niacin in patients already on aggressive LDL-C lowering treatment with statin with or without ezetimibe showed no benefit and identified new adverse effects of infection and bleeding in addition to the known adverse effects of niacin such as increasing glucose levels…”
BackgroundEffects of medical therapies on retinopathy progression in type 2 diabetes
The ACCORD Study Group and ACCORD Eye Study Group (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001288 · Cited by 1,311 · cited 1×
“control, reduced the rate of progression of diabetic retinopathy [39].”
BackgroundEffects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927 · cited 1×
“Two meta-analyses of large cardiovascular outcome studies with fibrates found they reduced the risk of major cardiovascular events predominantly by reduction of non-fatal myocardial infarction [35,36].”
Cited by
Hennuyer, N., Duplan, I., Paquet, C., Vanhoutte, J., Woitrain, E., Touche, V., Colin, S., Vallez, E., Lestavel, S., Lefebvre, P., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.03.003 · Cited by 132
Novel therapeutics in hypertriglyceridemia
Gryn, S. E., & Hegele, R. A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000231 · Cited by 44
Effects of pemafibrate on primary biliary cholangitis with dyslipidemia
Yamaguchi, M., Asano, T., Arisaka, T., Mashima, H., Irisawa, A., & Tamano, M. (2022) · Hepatology Research · doi:10.1111/hepr.13747 · Cited by 23
Metadata
- Authors
- Liu, Z.-M., Hu, M., Chan, P., & Tomlinson, B.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2015-01-21
- Volume
- 24
- Issue
- 5
- Pages
- 611-621
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2051656202
- Cited by
- 45
- References
- 23
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early investigational drugs targeting PPAR-α for the treatment of metabolic disease. https://app.cochat.ai/papers/10.1517/13543784.2015.1006359
- The paper
- Liu, Z.-M., Hu, M., Chan, P., & Tomlinson, B. (2015). Early investigational drugs targeting PPAR-α for the treatment of metabolic disease. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.2015.1006359
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.